JP2017525368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525368A5 JP2017525368A5 JP2017509733A JP2017509733A JP2017525368A5 JP 2017525368 A5 JP2017525368 A5 JP 2017525368A5 JP 2017509733 A JP2017509733 A JP 2017509733A JP 2017509733 A JP2017509733 A JP 2017509733A JP 2017525368 A5 JP2017525368 A5 JP 2017525368A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- goi
- binding fragment
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 32
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 11
- 102000003886 Glycoproteins Human genes 0.000 claims 9
- 108090000288 Glycoproteins Proteins 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 238000012258 culturing Methods 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 5
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039416P | 2014-08-19 | 2014-08-19 | |
| US62/039,416 | 2014-08-19 | ||
| PCT/US2015/045793 WO2016028838A1 (en) | 2014-08-19 | 2015-08-19 | Efficient selectivity of recombinant proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020132874A Division JP7260510B2 (ja) | 2014-08-19 | 2020-08-05 | 組み換え型タンパク質の効率的な選択性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525368A JP2017525368A (ja) | 2017-09-07 |
| JP2017525368A5 true JP2017525368A5 (enExample) | 2018-09-20 |
| JP7115851B2 JP7115851B2 (ja) | 2022-08-09 |
Family
ID=55347784
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509733A Active JP7115851B2 (ja) | 2014-08-19 | 2015-08-19 | 組み換え型タンパク質の効率的な選択性 |
| JP2020132874A Active JP7260510B2 (ja) | 2014-08-19 | 2020-08-05 | 組み換え型タンパク質の効率的な選択性 |
| JP2023061971A Active JP7561232B2 (ja) | 2014-08-19 | 2023-04-06 | 組み換え型タンパク質の効率的な選択性 |
| JP2024163845A Pending JP2024166420A (ja) | 2014-08-19 | 2024-09-20 | 組み換え型タンパク質の効率的な選択性 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020132874A Active JP7260510B2 (ja) | 2014-08-19 | 2020-08-05 | 組み換え型タンパク質の効率的な選択性 |
| JP2023061971A Active JP7561232B2 (ja) | 2014-08-19 | 2023-04-06 | 組み換え型タンパク質の効率的な選択性 |
| JP2024163845A Pending JP2024166420A (ja) | 2014-08-19 | 2024-09-20 | 組み換え型タンパク質の効率的な選択性 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9732357B2 (enExample) |
| EP (2) | EP3183359B1 (enExample) |
| JP (4) | JP7115851B2 (enExample) |
| KR (2) | KR102556383B1 (enExample) |
| CN (2) | CN113293139B (enExample) |
| AR (1) | AR102333A1 (enExample) |
| AU (3) | AU2015305565B9 (enExample) |
| CA (1) | CA2957036A1 (enExample) |
| CY (1) | CY1124079T1 (enExample) |
| DK (1) | DK3183359T3 (enExample) |
| EA (1) | EA035340B1 (enExample) |
| ES (1) | ES2849728T3 (enExample) |
| HR (1) | HRP20210301T1 (enExample) |
| HU (1) | HUE054069T2 (enExample) |
| IL (3) | IL287020B (enExample) |
| LT (1) | LT3183359T (enExample) |
| MA (1) | MA40371B1 (enExample) |
| MX (2) | MX384990B (enExample) |
| MY (1) | MY191745A (enExample) |
| PL (1) | PL3183359T3 (enExample) |
| PT (1) | PT3183359T (enExample) |
| RS (1) | RS61371B1 (enExample) |
| SG (2) | SG11201701121UA (enExample) |
| SI (1) | SI3183359T1 (enExample) |
| SM (1) | SMT202100054T1 (enExample) |
| TW (3) | TWI832364B (enExample) |
| WO (1) | WO2016028838A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102333A1 (es) | 2014-08-19 | 2017-02-22 | Regeneron Pharma | Selectividad eficiente de proteínas recombinadas |
| WO2019157395A1 (en) | 2018-02-08 | 2019-08-15 | Applied Stemcells, Inc | Methods for screening variant of target gene |
| CN114585597A (zh) | 2019-10-23 | 2022-06-03 | 佳能株式会社 | 制造陶瓷制品的方法和陶瓷制品 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US7192737B2 (en) | 2002-03-29 | 2007-03-20 | Xoma Technology Ltd. | Methods and materials for increasing expression of recombinant polypeptides |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| JP2005027599A (ja) | 2003-07-09 | 2005-02-03 | Nara Institute Of Science & Technology | 植物由来遺伝子を用いた遺伝子導入植物の選抜法 |
| EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| AR064200A1 (es) | 2006-12-07 | 2009-03-18 | Dow Agrosciences Llc | Genes marcadores seleccionables |
| ES2522615T3 (es) | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Regiones de expresión y estabilidad potenciadas |
| KR100927803B1 (ko) * | 2007-11-23 | 2009-11-23 | 한국생명공학연구원 | 식물 형질전환체를 선별하기 위한 마커로서 ｇｐｔ 유전자 |
| ES2570853T3 (es) * | 2007-12-07 | 2016-05-20 | Zymogenetics Inc | Moléculas de anticuerpo humanizadas específicas para IL-31 |
| US20110091495A1 (en) * | 2008-04-22 | 2011-04-21 | Rutgers, The State University Of New Jersey | Hcv e2 construct compositions and methods |
| US8927249B2 (en) * | 2008-12-09 | 2015-01-06 | Halozyme, Inc. | Extended soluble PH20 polypeptides and uses thereof |
| EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
| AR102333A1 (es) | 2014-08-19 | 2017-02-22 | Regeneron Pharma | Selectividad eficiente de proteínas recombinadas |
-
2015
- 2015-08-14 AR ARP150102631A patent/AR102333A1/es active IP Right Grant
- 2015-08-17 TW TW111129504A patent/TWI832364B/zh active
- 2015-08-17 TW TW104126657A patent/TWI719945B/zh active
- 2015-08-17 TW TW110101888A patent/TWI777374B/zh active
- 2015-08-19 CN CN202110402963.4A patent/CN113293139B/zh active Active
- 2015-08-19 AU AU2015305565A patent/AU2015305565B9/en active Active
- 2015-08-19 SG SG11201701121UA patent/SG11201701121UA/en unknown
- 2015-08-19 HU HUE15833421A patent/HUE054069T2/hu unknown
- 2015-08-19 EA EA201790241A patent/EA035340B1/ru unknown
- 2015-08-19 PL PL15833421T patent/PL3183359T3/pl unknown
- 2015-08-19 MY MYPI2017700248A patent/MY191745A/en unknown
- 2015-08-19 RS RS20210103A patent/RS61371B1/sr unknown
- 2015-08-19 US US14/829,834 patent/US9732357B2/en active Active
- 2015-08-19 WO PCT/US2015/045793 patent/WO2016028838A1/en not_active Ceased
- 2015-08-19 CA CA2957036A patent/CA2957036A1/en active Pending
- 2015-08-19 EP EP15833421.9A patent/EP3183359B1/en active Active
- 2015-08-19 LT LTEP15833421.9T patent/LT3183359T/lt unknown
- 2015-08-19 JP JP2017509733A patent/JP7115851B2/ja active Active
- 2015-08-19 KR KR1020227018877A patent/KR102556383B1/ko active Active
- 2015-08-19 SI SI201531487T patent/SI3183359T1/sl unknown
- 2015-08-19 SG SG10201707859RA patent/SG10201707859RA/en unknown
- 2015-08-19 IL IL287020A patent/IL287020B/en unknown
- 2015-08-19 MX MX2017002203A patent/MX384990B/es unknown
- 2015-08-19 CN CN201580044100.7A patent/CN107075549B/zh active Active
- 2015-08-19 SM SM20210054T patent/SMT202100054T1/it unknown
- 2015-08-19 HR HRP20210301TT patent/HRP20210301T1/hr unknown
- 2015-08-19 PT PT158334219T patent/PT3183359T/pt unknown
- 2015-08-19 DK DK15833421.9T patent/DK3183359T3/da active
- 2015-08-19 ES ES15833421T patent/ES2849728T3/es active Active
- 2015-08-19 KR KR1020177006620A patent/KR102406976B1/ko active Active
- 2015-08-19 EP EP20211902.0A patent/EP3901274A1/en active Pending
- 2015-08-19 MA MA40371A patent/MA40371B1/fr unknown
-
2017
- 2017-02-09 IL IL250531A patent/IL250531B/en unknown
- 2017-02-17 MX MX2021009154A patent/MX2021009154A/es unknown
- 2017-07-31 US US15/664,444 patent/US10457959B2/en active Active
-
2019
- 2019-09-10 US US16/566,253 patent/US11085053B2/en active Active
-
2020
- 2020-07-17 AU AU2020205336A patent/AU2020205336B2/en active Active
- 2020-08-05 JP JP2020132874A patent/JP7260510B2/ja active Active
-
2021
- 2021-02-08 CY CY20211100104T patent/CY1124079T1/el unknown
- 2021-07-02 US US17/366,239 patent/US20210340564A1/en not_active Abandoned
-
2022
- 2022-08-04 IL IL295361A patent/IL295361B2/en unknown
-
2023
- 2023-02-10 AU AU2023200752A patent/AU2023200752B2/en active Active
- 2023-04-06 JP JP2023061971A patent/JP7561232B2/ja active Active
-
2024
- 2024-09-20 JP JP2024163845A patent/JP2024166420A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111328288B (zh) | 靶向共同抗原的抗原结合蛋白 | |
| CN113784976B (zh) | 用于鉴定抗原特异性t细胞的组合物和方法 | |
| JP6608944B2 (ja) | 特徴が改変されたα溶血素変異体 | |
| US9127087B2 (en) | High affinity recombinant sea lamprey antibodies selected by a Yeast Surface Display platform | |
| JP2017513479A5 (enExample) | ||
| RU2016136855A (ru) | Биомаркер-направленная многоцелевая иммунотерапия | |
| Iwamoto et al. | Compositionally distinct nuclear pore complexes of functionally distinct dimorphic nuclei in the ciliate Tetrahymena | |
| JP7026906B2 (ja) | 転写調節融合ポリペプチド | |
| JP2017525368A5 (enExample) | ||
| EP2804875A1 (en) | Tools and methods for expression of membrane proteins | |
| CN119698427A (zh) | 用于预测hla ii类特异性表位和表征cd4+ t细胞的方法和系统 | |
| Ludwig et al. | High‐throughput single‐cell sequencing of paired TCRα and TCRβ genes for the direct expression‐cloning and functional analysis of murine T‐cell receptors | |
| US20190233843A1 (en) | Transposon system and methods of use | |
| Sadat et al. | GROEL/ES buffers entropic traps in folding pathway during evolution of a model substrate | |
| HRP20210301T1 (hr) | Djelotvorna selektivnost rekombinantnih proteina | |
| CN111448320B (zh) | 细胞膜穿透肽 | |
| JP6384685B2 (ja) | 組換えタンパク質の発現増進のための遺伝子断片を含むベクター及びその用途 | |
| JP2025519395A (ja) | ウイルスペプチド及びその使用 | |
| FI3687287T3 (fi) | Humanisoitua c1q-kompleksia ilmentävät jyrsijät | |
| EP4538285A1 (en) | Pd-1 variant and use thereof | |
| KR102655024B1 (ko) | 표적 특이적인 외래 유전자의 도입 방법 | |
| CN104711280B (zh) | 表达和纯化同时缺失外显子3和5 的α突触核蛋白选择性剪切体蛋白的方法 | |
| CN103524625B (zh) | 一种新型诱导抗体产生的方法 | |
| JP6795214B2 (ja) | ステロイドホルモン膜受容体の精製方法 | |
| CN102329377B (zh) | 狂犬病病毒优势表位肽抗原及其用途 |